SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

SCHEDULE OF CONCENTRATION RISK

The Company considers a significant customer to be one that comprises more than 10% of net revenues or accounts receivable. Customers that accounted for 10% or more of net revenues were as follows:

		For the Year Ended December 31, 2021			For the Year Ended December 31, 2020
	Segment	% of Revenue			% of Revenue
Customer A	Contract Services		20	%		–	%
Customer B	Regenerative Medicine Products		13	%		13	%
Customer C	Contract Services		18	%		41	%

Customers that accounted for 10% or more of accounts receivable were as follows:

		December 31, 2021			December 31, 2020
	Segment	% of Accounts Receivable			% of Accounts Receivable
Customer A	Contract Services		31	%		–	%
Customer B	Regenerative Medicine Products		–	%		14	%
Customer C	Contract Services		–	%		46	%
Customer F	Contract Services		17	%		–	%
Customer G	Contract Services		12	%		–	%

SCHEDULE OF REVENUE DISAGGREGATED BY SERVICES AND PRODUCTS

The following table contains revenues as presented in the Consolidated Statements of Operations disaggregated by services and products.

	For the Year Ended December 31, 2021		For the Year Ended December 31, 2020
Regenerative Medicine Products
SkinTE Products	$	3,076	$	3,730
Contract Services
Lab Testing Services		1,877		4,454
Preclinical Research Services		4,451		1,942
		6,328		6,396
Total Net Revenues	$	9,404	$	10,126